Veru Inc VERU 深 滬
等待開盤 03-26 09:30:00 美东时间
2.29
0.000
0.00%
華盛通- 最 高2.35
- 今 開2.32
- 成交量 2.96万股
- 最 低 2.265
- 昨 收 2.29
- 總市值 3675.52万
- 52周最高 7.40
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 2.10
- 委 比 -98.90%
- 總股本 1605.03万
- 歷史最高 245.70
- 量 比 0.47
- 振 幅 3.71%
- 歷史最低 2.14
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veru Inc. Publishes Corporate Presentation on Enobosarm-GLP-1 Obesity Program and Sabizabulin Atherosclerosis Development
Veru Inc. Publishes Corporate Presentation on Enobosarm-GLP-1 Obesity Program and Sabizabulin Atherosclerosis Development Veru Inc. outlined its cardiometabolic pipeline, highlighting enobosarm, an oral selective androgen receptor modulator, being developed in combination with a GLP-1 receptor agoni
03-02 22:39
Key deals this week: KORE, TopBuild, Equinix, PayPal and more
Here's a list of key deals reported across sectors this week: KORE Group Holdings (KORE) on Friday said that Searchlight Capital Partners and Abry Partners have entered into a definitive merger agreem...
03-01 04:15
Accenture offers AI opportunity after selloff, UBS says
Shares of Accenture (ACN) may be poised for a rebound after a 20% year-to-date decline, with UBS arguing the recent selloff has created an attractive entry point as artificial intelligence fears overs...
02-25 04:06
Accenture to buy Verum Partners
Accenture (ACN) has agreed to acquire Verum Partners to expand its capital projects capabilities in Latin America. Terms of the transaction were not disclosed. Completion is subject to customary closi...
02-24 20:45
Accenture Agrees To Acquire Verum Partners; Terms Undisclosed
Accenture (NYSE:ACN) has agreed to acquire Verum Partners, an infrastructure and capital projects management firm with deep expertise in the mining, metals, transportation, logistics, chemicals and energy industries.
02-24 20:18
Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference
Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference Veru Inc. (NASDAQ: VERU) said its Chairman, President and CEO Mitchell Steiner, M.D., will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, Feb. 26, 2026, from 3:20–
02-19 21:32
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Veru Inc. announced that its CEO, Mitchell Steiner, will present at the Oppenheimer Healthcare Conference on February 26, 2026. The event will be webcast live and archived on Veru's website. Veru focuses on developing innovative treatments for cardiometabolic and inflammatory diseases, with enobosarm and sabizabulin as key molecules. Enobosarm, a next-generation SARM, aims to enhance weight loss by selectively reducing fat while preserving lean m...
02-19 13:30
Veru Q1 EPS $(0.26) Beats $(0.47) Estimate
Veru (NASDAQ:VERU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.47) by 44.68 percent. This is a 57.38 percent increase over losses of $(0.61) per share from the same
02-11 19:31
Earnings Scheduled For February 11, 2026
Companies Reporting Before The Bell • SiteOne Landscape Supply (NYSE:SITE) is p...
02-11 19:11
Novo Nordisk warnt vor illegalen Semaglutid-Kopien von Hims & Hers
Novo Nordisk warnt vor illegalen Semaglutid-Kopien von Hims & Hers Novo Nordisk A/S hat eine Stellungnahme zu den von Hims & Hers angekündigten, nicht zugelassenen Nachahmer-Semaglutid-Pillen veröffentlicht. Das Unternehmen bezeichnet das Vorgehen von Hims & Hers als illegale Massenherstellung, die
02-05 23:50
